Abdom Radiol (NY)

1. HU M, Wei W, Zhang J, Wang S, et al
   Impact of virtual monochromatic images of different low-energy levels in dual-energy CT on radiomics models for predicting muscle invasion in bladder cancer.
   Abdom Radiol (NY). 2024 Jun 27. doi: 10.1007/s00261-024-04459.
   

   >> Share

   
   
2. XUE J, Zhuang Z, Peng L, Chen X, et al
   Prognostic predictive value of urothelial carcinoma of the bladder after TURBT based on multiphase CT radiomics.
   Abdom Radiol (NY). 2024;49:1975-1986.
   

   >> Share

   
   

   
   Adv Sci (Weinh)

3. YAN P, Wang G, Huang M, Liu Z, et al
   Combinatorial Biosynthesis Creates a Novel Aglycone Polyether with High Potency and Low Side Effects Against Bladder Cancer.
   Adv Sci (Weinh). 2024 Jun 27:e2404668. doi: 10.1002/advs.202404668.
   

   >> Share

   
   
4. XIAO Y, Jin W, Qian K, Ju L, et al
   Integrative Single Cell Atlas Revealed Intratumoral Heterogeneity Generation from an Adaptive Epigenetic Cell State in Human Bladder Urothelial Carcinoma.
   Adv Sci (Weinh). 2024;11:e2308438.
   

   >> Share

   
   

   
   Arch Ital Urol Androl

5. FARCI R, Tolu S, Trombetta M, Murgia A, et al
   An unusual "linitis plastica" like breast cancer bladder metastasis.
   Arch Ital Urol Androl. 2024;96:12483.
   

   >> Share

   
   

   
   Asian Pac J Cancer Prev

6. ELFIEKY MMM, Abd El Rahman M, Fayed AM, Haleem Al-Qaim Z, et al
   Relapse and Survival in Bladder Cancer Patients Undergoing microRNA-129 and microRNA-145 Assays.
   Asian Pac J Cancer Prev. 2024;25:2113-2121.
   

   >> Share

   
   

   
   BJU Int

7. FLAMMIA RS, Tuderti G, Bologna E, Minore A, et al
   Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
   BJU Int. 2024 Jun 24. doi: 10.1111/bju.16440.
   

   >> Share

   
   
8. WOLFF I, Kravchuk AP, Wirtz RM, Schlomm T, et al
   Real-world performance of Uromonitor(R) in urothelial bladder cancer detection: a multicentric trial.
   BJU Int. 2024 Jun 24. doi: 10.1111/bju.16450.
   

   >> Share

   
   

   
   Bladder Cancer

9. CHANDI J, Soundararajan S, Bukowski W, Britt W, et al
   Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors.
   Bladder Cancer. 2024;10:61-69.
   

   >> Share

   
   

   
   Brief Bioinform

10. WEI PJ, Guo Z, Gao Z, Ding Z, et al
    Inference of gene regulatory networks based on directed graph convolutional networks.
    Brief Bioinform. 2024;25:bbae309.
    

    >> Share

    
    

    
    Can J Urol

11. VLACHOU E, Johnson ? BA, Guancial E, Lombardo KA, et al
    Frontline immune checkpoint inhibitors in patients >/= 90 years with advanced urothelial cancer: a single center experience.
    Can J Urol. 2024;31:11875-11879.
    

    >> Share

    
    

    
    Cancer Immunol Res

12. YOLMO P, Rahimi S, Chenard S, Conseil G, et al
    Atypical B cells promote cancer progression and poor response to Bacillus Calmette-Guerin in non-muscle invasive bladder cancer.
    Cancer Immunol Res. 2024 Jun 25. doi: 10.1158/2326-6066.CIR-23-1114.
    

    >> Share

    
    

    
    Cancer Med

13. ESCOTT M, Yi Y, Foret A, Li T, et al
    Impact of rural location on receipt of standard of care treatment and survival for locally advanced bladder cancer in Louisiana.
    Cancer Med. 2024;13:e7301.
    

    >> Share

    
    
14. MANITZ J, Gerhold-Ay A, Kieslich P, Shah P, et al
    Avelumab first-line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial.
    Cancer Med. 2024;13:e7411.
    

    >> Share

    
    

    
    Cancer Rep (Hoboken)

15. ARIHARA Y, Omori G, Kobayashi K, Sugita S, et al
    Marked Response to Nivolumab by a Patient With SMARCA4-Deficient Undifferentiated Urothelial Carcinoma Showing High PD-L1 Expression: A Case Report.
    Cancer Rep (Hoboken). 2024;7:e2127.
    

    >> Share

    
    

    
    Cancers (Basel)

16. FERRARIO N, Marras E, Vivona V, Randisi F, et al
    Mechanisms of the Antineoplastic Effects of New Fluoroquinolones in 2D and 3D Human Breast and Bladder Cancer Cell Lines.
    Cancers (Basel). 2024;16:2227.
    

    >> Share

    
    
17. DESPONDS E, Kioseoglou K, Zdimerova H, Ongaro M, et al
    Development of Traceable Mouse Models of Advanced and Metastatic Bladder Cancer.
    Cancers (Basel). 2024;16:2245.
    

    >> Share

    
    

    
    Clin Biochem

18. AALAMI AH, Abdeahad H, Aalami F, Sathyapalan T, et al
    Investigating angiogenin/ribonuclease 5 as a diagnostic biomarker for bladder cancer: In-depth analysis from a systematic review and meta-analysis.
    Clin Biochem. 2024 Jun 19:110780. doi: 10.1016/j.clinbiochem.2024.110780.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

19. DEWULF K, Richter K, Illy M, Branger N, et al
    Can Bladder MRI Improve the Follow-Up of Non-Muscle-Invasive Bladder Cancer by Detecting Endoscopic Invisible Recurrence?
    Clin Genitourin Cancer. 2024;22:102136.
    

    >> Share

    
    

    
    Curr Oncol

20. MOUSSA MJ, Khandelwal J, Wilson NR, Naik SA, et al
    Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy.
    Curr Oncol. 2024;31:3342-3349.
    

    >> Share

    
    

    
    Discov Oncol

21. XIONG H, Lin C, Huang X, Wang H, et al
    A novel mitochondrial-related lncRNA signature mediated prediction of overall survival, immune landscape, and the chemotherapeutic outcomes for bladder cancer patients.
    Discov Oncol. 2024;15:239.
    

    >> Share

    
    

    
    Eur J Dermatol

22. YOSHITANI S, Kaneda K, Nishida M, Komura K, et al
    A case of urothelial carcinoma with successful continuation of enfortumab vedotin without dose reduction despite grade 3 diffuse erythema with fever.
    Eur J Dermatol. 2024;34:214-216.
    

    >> Share

    
    

    
    Eur Urol Oncol

23. SORIA F, Rosazza M, Livoti S, Moschini M, et al
    Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaborati
    Eur Urol Oncol. 2024 Jun 20:S2588-9311(24)00151.
    

    >> Share

    
    
24. MERTENS LS, Bruins HM, Contieri R, Babjuk M, et al
    Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels.
    Eur Urol Oncol. 2024 Jun 20:S2588-9311(24)00141.
    

    >> Share

    
    

    
    Front Endocrinol (Lausanne)

25. NGUYEN T, Ordulu Z, Shrestha S, Patel U, et al
    Case report: A novel somatic SDHB variant in a patient with bladder paraganglioma.
    Front Endocrinol (Lausanne). 2024;15:1386285.
    

    >> Share

    
    

    
    Front Immunol

26. KONG J, Zou Y, Zhou H, Huang Y, et al
    Assessing the predictive value of smoking history for immunotherapy outcomes in bladder cancer patients.
    Front Immunol. 2024;15:1404812.
    

    >> Share

    
    

    
    In Vivo

27. MINATO A, Ohno D, Murooka K, Okumura Y, et al
    Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
    In Vivo. 2024;38:1927-1934.
    

    >> Share

    
    
28. PEPE P, Salemi M, Marchese G, Salluzzo MG, et al
    Transcriptome Analysis in Patients With Muscle-invasive Bladder Cancer.
    In Vivo. 2024;38:1660-1664.
    

    >> Share

    
    

    
    Int J Biol Macromol

29. QIN J, Li Z, Su L, Wen X, et al
    Expression of transferrin receptor/TFRC protein in bladder cancer cell T24 and its role in inducing iron death in bladder cancer.
    Int J Biol Macromol. 2024;274.
    

    >> Share

    
    

    
    Int J Mol Sci

30. SMOLKA C, Eckstein M, Jung R, Lieb V, et al
    Prognostic and Predictive Potential of CCL5 Expression in Muscle-Invasive Bladder Cancer Patients.
    Int J Mol Sci. 2024;25:6325.
    

    >> Share

    
    
31. GERMANA E, Pepe L, Pizzimenti C, Ballato M, et al
    Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications.
    Int J Mol Sci. 2024;25:6750.
    

    >> Share

    
    

    
    Int J Surg

32. LIU H, Chen J, Huang Y, Zhang Y, et al
    Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis.
    Int J Surg. 2024;110:3923-3936.
    

    >> Share

    
    

    
    Iran J Public Health

33. PENG F, Meng Y, Sun L, Dong B, et al
    People-Oriented Nursing Mode on the Negative Emotions and Psychological Status of Patients with Bladder Cancer.
    Iran J Public Health. 2024;53:1087-1095.
    

    >> Share

    
    

    
    J Am Acad Dermatol

34. BANNER L, Rohan TZ, Zachian R, Gross T, et al
    Increased incidence of thyroid, renal, lung, melanoma, bladder, and prostate cancers after diagnosis of primary cutaneous B-cell lymphoma: A SEER database analysis.
    J Am Acad Dermatol. 2024 Mar 19:S0190-9622(24)00505.
    

    >> Share

    
    

    
    J Biophotonics

35. SU W, Xu C, Hu J, Chen Q, et al
    Non-invasive screening of bladder cancer using digital microfluidics and FLIM technology combined with deep learning.
    J Biophotonics. 2024 Jun 28:e202400192. doi: 10.1002/jbio.202400192.
    

    >> Share

    
    

    
    J Cancer

36. HU Z, Liu C, Mei Z, Wang X, et al
    A-to-I edited miR-154-p13-5p inhibited cell proliferation and migration and induced apoptosis by targeting LIX1L in the bladder cancer.
    J Cancer. 2024;15:3708-3723.
    

    >> Share

    
    
37. XIAO H, Huang X, Chen H, Zheng Y, et al
    Establishment of a SUMO pathway related gene signature for predicting prognosis, chemotherapy response and investigating the role of EGR2 in bladder cancer.
    J Cancer. 2024;15:3841-3856.
    

    >> Share

    
    

    
    J Formos Med Assoc

38. LEE IW, Wang HJ, Liu HY, Chang YL, et al
    Prevalence and oncologic impact of chronic kidney disease for upper tract urothelial carcinoma in endemic area.
    J Formos Med Assoc. 2024;123:758-763.
    

    >> Share

    
    

    
    J Physiol Investig

39. RAO P, Li J, Xiong J, Shen S, et al
    MicroRNA-150-5p-mediated Inhibition of Cell Proliferation, G1/S Transition, and Migration in Bladder Cancer through Targeting NEDD4-binding Protein 2-like 1 Gene.
    J Physiol Investig. 2024;67:118-128.
    

    >> Share

    
    

    
    J Urol

40. LINSCOTT J, Li R
    Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
    J Urol. 2024 Jun 24:101097JU0000000000004122. doi: 10.1097/JU.0000000000004122.
    

    >> Share

    
    

    
    Metabolites

41. ZHOU D, Huang J, Zheng H, Liu Y, et al
    Insight into Fructose-to-Sucrose Ratio as the Potential Target of Urinalysis in Bladder Cancer.
    Metabolites. 2024;14:345.
    

    >> Share

    
    

    
    Minerva Urol Nephrol

42. DEL GIUDICE F, Tresh A, Li S, Basran S, et al
    The impact of venous thromboembolism before open or minimally-invasive radical cystectomy in the USA: insurance claims data on perioperative outcomes and healthcare costs.
    Minerva Urol Nephrol. 2024;76:320-330.
    

    >> Share

    
    

    
    Mod Pathol

43. VLAJNIC T, Chijioke O, Roma L, Savic Prince S, et al
    Loss of MTAP Expression by Immunohistochemistry Is a Surrogate Marker for Homozygous 9p21.3 Deletion in Urothelial Carcinoma.
    Mod Pathol. 2024;37:100495.
    

    >> Share

    
    

    
    Molecules

44. ELEZ-BURNJAKOVIC N, Pojskic L, Haveric A, Lojo-Kadric N, et al
    Halogenated Boroxine K(2)[B(3)O(3)F(4)OH] Modulates Metabolic Phenotype and Autophagy in Human Bladder Carcinoma 5637 Cell Line.
    Molecules. 2024;29:2919.
    

    >> Share

    
    

    
    Nat Rev Clin Oncol

45. AGGEN DH, Rosenberg JE
    Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma.
    Nat Rev Clin Oncol. 2024;21:487-488.
    

    >> Share

    
    

    
    Nutrients

46. KANG M, Wilkens LR, Wirth MD, Shivappa N, et al
    Diet Quality and Risk of Bladder Cancer in the Multiethnic Cohort Study.
    Nutrients. 2024;16:1965.
    

    >> Share

    
    

    
    Panminerva Med

47. SU L, Wang Y, Ma J
    Analysis of the short-term efficacy and impact on the quality of life of patients with bladder cancer after surgery treated with Shenhu soup empirical formula combined with bladder perfusion.
    Panminerva Med. 2024 Jun 27. doi: 10.23736/S0031-0808.24.05136.
    

    >> Share

    
    

    
    Pharmacol Res

48. KASEB H, Leslie SW, Soon-Sutton TL, Aeddula NR, et al
    Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: Implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma.
    Pharmacol Res. 2024;205:107230.
    

    >> Share

    
    

    
    Sci Data

49. XU PH, Li T, Qu F, Tian M, et al
    Comprehensive Collection of Whole-Slide Images and Genomic Profiles for Patients with Bladder Cancer.
    Sci Data. 2024;11:699.
    

    >> Share

    
    

    
    Sci Rep

50. YAN Z, Liu Y, Wang M, Wang L, et al
    A novel signature constructed by mitochondrial function and cell death-related gene for the prediction of prognosis in bladder cancer.
    Sci Rep. 2024;14:14667.
    

    >> Share

    
    
51. WU J, Zhang F, Zheng X, Chen D, et al
    Identification of bladder cancer subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes.
    Sci Rep. 2024;14:14431.
    

    >> Share

    
    

    
    Urol Oncol

52. RANGANATHAN S, Riveros C, Xu J, Hu S, et al
    Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.
    Urol Oncol. 2024;42:291.
    

    >> Share

    
    

    
    Urology

53. CABRAL JD, Modi PK
    Editorial Comment on "Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer".
    Urology. 2024 Jun 20:S0090-4295(24)00469-2. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    
54. LIU WJ, Campbell RA, Michael PD, Wood A, et al
    Clinical upstaging after neoadjuvant chemotherapy impacting eligibility for vaginal-sparing cystectomy: identifying bladder cancer patients who may benefit from interim imaging.
    Urology. 2024 Jun 20:S0090-4295(24)00474-6. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    
55. REFUGIA JM, Roebuck E, Thakker P, Sandberg M, et al
    Sequential Intravesical Chemotherapy for Treatment Naive, High-Risk Non-Muscle Invasive Bladder Cancer: Oncologic Outcomes, Tolerance, and Comparison to Contemporary Controls.
    Urology. 2024 Jun 19:S0090-4295(24)00463-1. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    
56. CONNORS C, Wang D, Levy M, Ravivarapu KT, et al
    Transurethral Resection of Bladder Tumor Outcomes Are Predicted by a 5-Item Frailty Index.
    Urology. 2024;188:104-110.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share